Drugs without bio-equivalency proof to exit from markets.

Effective from Nov. this year under the new MOHW provision, the NHI reimbursement plan will not be applicable for the drugs that were not proven with their bio-equivalency. This may give a serious impact to the drug industry who failed the test as the technical environment was too premature to conduct.

According to the drug industry, they submitted all necessary documentations for the test t...